Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Amortizatization of Intangibles (2020 - 2025)

Historic Amortizatization of Intangibles for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to $1.1 million.

  • Journey Medical's Amortizatization of Intangibles rose 3071.25% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 2815.47%. This contributed to the annual value of $3.4 million for FY2024, which is 910.54% down from last year.
  • Journey Medical's Amortizatization of Intangibles amounted to $1.1 million in Q3 2025, which was up 3071.25% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Journey Medical's Amortizatization of Intangibles registered a high of $1.2 million during Q4 2022, and its lowest value of $572000.0 during Q4 2021.
  • Over the past 5 years, Journey Medical's median Amortizatization of Intangibles value was $981000.0 (recorded in 2024), while the average stood at $904368.4.
  • Per our database at Business Quant, Journey Medical's Amortizatization of Intangibles soared by 11451.05% in 2022 and then tumbled by 3357.78% in 2023.
  • Over the past 5 years, Journey Medical's Amortizatization of Intangibles (Quarter) stood at $572000.0 in 2021, then soared by 114.51% to $1.2 million in 2022, then crashed by 33.58% to $815000.0 in 2023, then rose by 20.37% to $981000.0 in 2024, then grew by 8.46% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.1 million for Q2 2025, and $1.1 million during Q1 2025.